Craig M Brackett
Overview
Explore the profile of Craig M Brackett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
378
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yang H, Brackett C, Morales-Tirado V, Li Z, Zhang Q, Wilson M, et al.
Oncotarget
. 2015 Dec;
7(3):2936-50.
PMID: 26655090
Uveal melanoma (UM) is the most common primary cancer of the eye in adults and progresses to metastatic disease predominantly of the liver in ~50% of patients. In these cases,...
12.
Kojouharov B, Brackett C, Veith J, Johnson C, Gitlin I, Toshkov I, et al.
Oncotarget
. 2014 Mar;
5(3):802-14.
PMID: 24583651
Myelosuppression and gastrointestinal damage are common side effects of cancer treatment limiting efficacy of DNA-damaging chemotherapeutic drugs. The Toll-like receptor 5 (TLR5) agonist Entolimod has demonstrated efficacy in mitigating damage...
13.
Brackett C, Muhitch J, Evans S, Gollnick S
J Immunol
. 2013 Sep;
191(8):4348-57.
PMID: 24026079
Blood-borne neutrophils are excluded from entering lymph nodes across vascular portals termed high endothelial venules (HEVs) because of lack of expression of the CCR7 homeostatic chemokine receptor. Induction of sterile...
14.
Burdelya L, Brackett C, Kojouharov B, Gitlin I, Leonova K, Gleiberman A, et al.
Proc Natl Acad Sci U S A
. 2013 May;
110(20):E1857-66.
PMID: 23630282
Vertebrate Toll-like receptor 5 (TLR5) recognizes bacterial flagellin proteins and activates innate immune responses to motile bacteria. In addition, activation of TLR5 signaling can inhibit growth of TLR5-expressing tumors and...
15.
Brackett C, Owczarczak B, Ramsey K, Maier P, Gollnick S
Lasers Surg Med
. 2011 Nov;
43(7):676-85.
PMID: 22057495
Background And Objective: Photodynamic therapy (PDT) is an anticancer modality approved for the treatment of early disease and palliation of late stage disease. PDT of tumors results in the generation...
16.
Brackett C, Gollnick S
Photochem Photobiol Sci
. 2011 Jan;
10(5):649-52.
PMID: 21253659
Photodynamic therapy (PDT) is an FDA-approved modality for the treatment of early-stage disease and palliation of late-stage disease. Pre-clinical studies using mouse models and clinical studies in patients have demonstrated...
17.
Gollnick S, Brackett C
Immunol Res
. 2009 Sep;
46(1-3):216-26.
PMID: 19763892
Photodynamic therapy (PDT) is an FDA-approved modality that rapidly eliminates local tumors, resulting in cure of early disease and palliation of advanced disease. PDT was originally considered to be a...